Visceral adiposity index and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism

C. Haymana; A. Sonmez; A. Aydogdu; A. Taslipinar; C. Meric; Y. Basaran; K. Baskoy; S. Tapan; G. Uckaya; E. Bolu; O. Azal

P1047

Prev Next

Section Contents Cite

Endocrine Abstracts (2012) 29 P1047

ICEECE2012 Poster Presentations Male Reproduction (63 abstracts)

Visceral adiposity index and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism

C. Haymana , A. Sonmez , A. Aydogdu , A. Taslipinar , C. Meric , Y. Basaran , K. Baskoy , S. Tapan , G. Uckaya , E. Bolu & O. Azal

View

Author affiliations

Gulhane School of Medicine, Etlik, Turkey.

Introduction: Visceral adipose tissue (VAT) is closely related to metabolic derangement, such as dyslipidemia insulin resistance and type 2 diabetes. Also, there is an increase in deposition of visceral adipose tissue in hypogonadal subjects. The visceral adiposity index (VAI) is a sex-specific mathematical index, based on waist circumference (WC), body mass index (BMI), triglycerides (TG) and HDL cholesterol (HDL) levels, indirectly expressing visceral adipose function. We investigated the VAI in treatment-naive, young men with congenital hypogonadal hypogonadism (CHH) and searched for the effect of testosterone replacement on the VAI of this specific patient group.

Description of methods/design: A total of 190 patients (age 21.9±2.25 years) were enrolled. The control group included 200 age and BMI matched healthy young men (age 21.7±1.5 years). Standard regimen of testosterone esters (250 mg/3 weeks) was given to patients.

Results: The levels of VAI was higher in CHH (P<0.0001) according to healthy controls. The patients had higher WC, TG, HDL cholesterol (P<0.001 for all) levels (Table 1). After 5.52±2.5 months of testosterone treatment WC (P<0.0001), TG (P<0.019), VAI (P<0.002) levels were increased and HDL cholesterol levels were decreased (P<0.0001; Table 1).

**Table 1** The metabolic profiles of the patients with hypogonadism and healthy volunteers
	Patients (n: 190)		Controls (n: 200)	p1	p2
	Before treatment	After Treatment
Age (years)	21.9±2.25	–	21.7±1.5	0.23	–
BMI (kg/m²)	22.0±3.74	22.9±3.3	21.9±1.1	0.179	0.0001
WC (cm)	82.8±10.8	85.6±9.9	76±4.7	0.0001	0.0001
SBP (mmHg)	112.4±9.6	116.1±10.5	107.5±10.7	0.0001	0.001
DBP (mmHg)	71.9±8.0	72.4±8.6	67.7±9.0	0.0001	0.23
TG (mg/dl)	102.5±46.8	109.2±43.5	81.4±42.9	0.0001	0.019
HDL (mg/dl)	46.7±11.4	42.6±10.6	53.1±9.8	0.0001	0.0001
VAI	3.1±1.8	3.6±1.6	2.0±1.4	0.0001	0.002
p1, patients vs controls; p2, before treatment vs after treatment; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, trigliseride; HDL, high density lipoprotein; VAI, visceral adiposity index.

Conclusion: This study shows that VAI levels are increased in treatment-naive, young men with CHH and after the testosterone replacement, the VAI levels are increased further.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.